Thyrocare FY26: PAT Surges 81%, Board Approves Auditor Change and Director Rejig
Thyrocare Technologies reported strong FY26 results with consolidated PAT surging 81% to Rs. 162.85 crore and revenue growing 21% to Rs. 829.04 crore. The Board recommended a final dividend of Rs. 7.00 per share, approved Price Waterhouse as new statutory auditors, re-appointed MD & CEO Rahul Guha, inducted two new directors, and approved a Rs. 5.50 crore investment in wholly owned subsidiary Think Health Diagnostics.
